Arbutus Biopharma Corp Net Income
| ABUS Stock | USD 3.84 0.17 4.63% |
As of the 7th of February, Arbutus Biopharma shows the risk adjusted performance of (0.04), and Mean Deviation of 2.58. Arbutus Biopharma Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Arbutus Biopharma Corp risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Arbutus Biopharma Corp is priced correctly, providing market reflects its regular price of 3.84 per share. Given that Arbutus Biopharma has information ratio of (0.08), we suggest you to validate Arbutus Biopharma Corp's prevailing market performance to make sure the company can sustain itself at a future point.
Arbutus Biopharma Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 44.6717 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -62.9 M | -66.1 M | |
| Net Loss | -62.9 M | -66.1 M | |
| Net Loss | -62.5 M | -65.6 M | |
| Net Loss | (0.34) | (0.36) | |
| Net Income Per E B T | 1.23 | 1.03 |
Arbutus | Net Income | Build AI portfolio with Arbutus Stock |
The evolution of Net Income for Arbutus Biopharma Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Arbutus Biopharma compares to historical norms and industry peers.
Latest Arbutus Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of Arbutus Biopharma Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Arbutus Biopharma Corp financial statement analysis. It represents the amount of money remaining after all of Arbutus Biopharma Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Arbutus Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (69.92 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Arbutus Net Income Regression Statistics
| Arithmetic Mean | (74,298,009) | |
| Geometric Mean | 52,469,180 | |
| Coefficient Of Variation | (120.12) | |
| Mean Deviation | 47,209,172 | |
| Median | (63,745,000) | |
| Standard Deviation | 89,244,746 | |
| Sample Variance | 7964.6T | |
| Range | 414M | |
| R-Value | (0.18) | |
| Mean Square Error | 8210.6T | |
| R-Squared | 0.03 | |
| Significance | 0.48 | |
| Slope | (3,236,957) | |
| Total Sum of Squares | 127434T |
Arbutus Net Income History
Other Fundumenentals of Arbutus Biopharma Corp
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Arbutus Biopharma Net Income component correlations
Arbutus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Arbutus Biopharma is extremely important. It helps to project a fair market value of Arbutus Stock properly, considering its historical fundamentals such as Net Income. Since Arbutus Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arbutus Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arbutus Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Arbutus introduce new products? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.23) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Arbutus Biopharma Corp's market price often diverges from its book value, the accounting figure shown on Arbutus's balance sheet. Smart investors calculate Arbutus Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Arbutus Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Arbutus Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Arbutus Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arbutus Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arbutus Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arbutus Biopharma.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Arbutus Biopharma on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Arbutus Biopharma Corp or generate 0.0% return on investment in Arbutus Biopharma over 90 days. Arbutus Biopharma is related to or competes with ARS Pharmaceuticals, Nanobiotix, GH Research, Tango Therapeutics, Bicara Therapeutics, Septerna Common, and Eyepoint Pharmaceuticals. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus in... More
Arbutus Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arbutus Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arbutus Biopharma Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 20.16 | |||
| Value At Risk | (5.79) | |||
| Potential Upside | 5.33 |
Arbutus Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arbutus Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arbutus Biopharma's standard deviation. In reality, there are many statistical measures that can use Arbutus Biopharma historical prices to predict the future Arbutus Biopharma's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.56) | |||
| Treynor Ratio | (0.16) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arbutus Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arbutus Biopharma February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 2.58 | |||
| Coefficient Of Variation | (1,711) | |||
| Standard Deviation | 3.5 | |||
| Variance | 12.28 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.56) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 20.16 | |||
| Value At Risk | (5.79) | |||
| Potential Upside | 5.33 | |||
| Skewness | (0.80) | |||
| Kurtosis | 2.36 |
Arbutus Biopharma Corp Backtested Returns
Arbutus Biopharma Corp secures Sharpe Ratio (or Efficiency) of -0.0635, which signifies that the company had a -0.0635 % return per unit of standard deviation over the last 3 months. Arbutus Biopharma Corp exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Arbutus Biopharma's risk adjusted performance of (0.04), and Mean Deviation of 2.58 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.35, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arbutus Biopharma will likely underperform. At this point, Arbutus Biopharma Corp has a negative expected return of -0.23%. Please make sure to confirm Arbutus Biopharma's information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if Arbutus Biopharma Corp performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.24 |
Weak reverse predictability
Arbutus Biopharma Corp has weak reverse predictability. Overlapping area represents the amount of predictability between Arbutus Biopharma time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arbutus Biopharma Corp price movement. The serial correlation of -0.24 indicates that over 24.0% of current Arbutus Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.24 | |
| Spearman Rank Test | -0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Arbutus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Arbutus Biopharma Corp reported net income of (69.92 Million). This is 120.49% lower than that of the Biotechnology sector and 199.82% lower than that of the Health Care industry. The net income for all United States stocks is 112.25% higher than that of the company.
Arbutus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arbutus Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics of similar companies.Arbutus Biopharma is currently under evaluation in net income category among its peers.
Arbutus Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arbutus Biopharma from analyzing Arbutus Biopharma's financial statements. These drivers represent accounts that assess Arbutus Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arbutus Biopharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 413.3M | 351.7M | 414.9M | 606.9M | 546.2M | 573.6M | |
| Enterprise Value | 322.9M | 333.5M | 397.3M | 571.9M | 514.7M | 540.4M |
Arbutus Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arbutus Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arbutus Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Arbutus Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Arbutus Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Arbutus Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arbutus Biopharma's value.| Shares | Foursixthree Capital Lp | 2025-06-30 | 2.6 M | Woodline Partners Lp | 2025-06-30 | 2.5 M | Rubric Capital Management Lp | 2025-06-30 | 1.6 M | Advisor Group Holdings, Inc. | 2025-06-30 | 1.3 M | Northern Trust Corp | 2025-06-30 | 1.3 M | Saba Capital Management, Lp | 2025-06-30 | 1.3 M | Charles Schwab Investment Management Inc | 2025-06-30 | 1.3 M | Fourworld Capital Management Llc | 2025-06-30 | 1.2 M | Bank Of America Corp | 2025-06-30 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 24.2 M | Whitefort Capital Management, Lp. | 2025-06-30 | 13.3 M |
Arbutus Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.89) % | ||||
| Operating Margin | (15.68) % | ||||
| Current Valuation | 652.48 M | ||||
| Shares Outstanding | 192.32 M | ||||
| Shares Owned By Insiders | 21.80 % | ||||
| Shares Owned By Institutions | 62.15 % | ||||
| Number Of Shares Shorted | 13.07 M | ||||
| Price To Earning | (1.16) X | ||||
| Price To Book | 9.63 X | ||||
| Price To Sales | 48.32 X | ||||
| Revenue | 6.17 M | ||||
| Gross Profit | (14.44 M) | ||||
| EBITDA | (68.4 M) | ||||
| Net Income | (69.92 M) | ||||
| Cash And Equivalents | 150.2 M | ||||
| Cash Per Share | 1.00 X | ||||
| Total Debt | 1.29 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 0.40 X | ||||
| Cash Flow From Operations | (64.85 M) | ||||
| Short Ratio | 9.83 X | ||||
| Earnings Per Share | (0.23) X | ||||
| Target Price | 5.74 | ||||
| Number Of Employees | 44 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 705.83 M | ||||
| Total Asset | 131.71 M | ||||
| Retained Earnings | (1.35 B) | ||||
| Working Capital | 111.7 M | ||||
| Current Asset | 183.88 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 131.71 M |
About Arbutus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.